What Is Ipamorelin? Mechanism and Evidence
TL;DR: Ipamorelin is a synthetic pentapeptide and selective agonist of the growth hormone secretagogue receptor (GHS-R1a), studied in preclinical rodent and swine models for its ability to stimulate pulsatile growth hormone (GH) release from the pituitary. Its documented selectivity profile — notably its lack of significant ACTH or cortisol elevation at GH-releasing doses, unlike older GHRPs — has made it a reference compound in GH-axis research. Human data is limited to pharmacokinetic studies. Ipamorelin is not FDA approved for any human use and is classified by WADA as prohibited under Section S2.
Research-Use Disclaimer: This article is for educational and research reference purposes only. Ipamorelin is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical and pharmacokinetic research. For adults 18+ with a research interest only.
What Is Ipamorelin? Definition and Structure
Ipamorelin is a synthetic pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It belongs to the growth hormone secretagogue (GHS) class — a family of compounds that stimulate GH release by acting on the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin.
Unlike ghrelin itself — a 28-amino acid gut-derived peptide — ipamorelin is a short, highly stable synthetic analog developed through a systematic medicinal chemistry program. It was first described in the peer-reviewed literature in 1998 by Raun et al. at Novo Nordisk, who identified it within a series of compounds structurally derived from GHRP-1 but lacking the central Ala-Trp dipeptide. This structural difference is associated with its distinct selectivity profile.
In the Legendary Labz Peptide Research Guide, ipamorelin is categorized within the GH Axis & Secretagogues cluster, alongside CJC-1295 and related compounds, and is assigned an evidence tier of Tier 2: multiple peer-reviewed preclinical studies; limited human pharmacokinetic data.
How Does Ipamorelin Work? The GHS-R1a Mechanism
Ipamorelin stimulates GH release by binding as an agonist to the GHS-R1a receptor — a G protein-coupled receptor (GPCR) expressed on somatotroph cells in the anterior pituitary gland. Activation of GHS-R1a triggers intracellular signaling cascades that result in episodic, pulsatile GH secretion.
What Does GHS-R1a Activation Actually Do in Preclinical Studies?
According to PubMed-indexed research, GHS-R1a agonism by ipamorelin produces a measurable, dose-dependent GH pulse. The landmark 1998 pharmacology study by Raun et al., published in the European Journal of Endocrinology, demonstrated that ipamorelin stimulated GH release in both anesthetized rats and conscious swine with potency and efficacy comparable to GHRP-6 — with an ED50 in swine of 2.3 nmol/kg and a peak plasma GH of 65 ng/mL. Crucially, this study also characterized ipamorelin's receptor pharmacology using GHRP and GHRH antagonists, confirming that the mechanism operates through a GHRP-like (GHS-R) receptor pathway rather than the GHRH receptor.
A complementary pharmacokinetic study by Johansen et al. (1998), published in Xenobiotica, compared ipamorelin to GHRP-2 and GHRP-6 and found that ipamorelin had a systemic plasma clearance approximately 5-fold lower than GHRP-6 following intravenous bolus in rats, with 60–80% of administered dose recoverable as intact peptide from bile and urine — indicating moderate resistance to metabolic degradation.
What Is Ipamorelin's Selectivity Profile Compared to Older GHRPs?
The selectivity of ipamorelin for GH release relative to other pituitary hormones is its most extensively documented distinguishing feature in the preclinical literature. In the Raun et al. (1998) study, administration of both GHRP-6 and GHRP-2 in swine produced significant elevations in plasma ACTH and cortisol, while ipamorelin did not raise ACTH or cortisol to levels significantly different from GHRH stimulation alone — even at doses more than 200-fold above the GH-releasing ED50. FSH, LH, prolactin (PRL), and TSH were unaffected by all GHSs tested. The authors described ipamorelin as "the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH."
A separate medicinal chemistry study by Ankersen et al. (1998), published in the Journal of Medicinal Chemistry, used ipamorelin as the structural scaffold from which a new series of GH secretagogues was derived, confirming ipamorelin's in vitro and in vivo GH-releasing potency as a reference standard in the GHS field.
What Does the Preclinical and Human Research Show?
Longitudinal Bone Growth in Rodent Models
A 1999 study by Johansen et al., published in Growth Hormone & IGF Research, administered ipamorelin subcutaneously three times daily for 15 days to adult female rats and measured longitudinal bone growth rate (LGR) via intravital tetracycline labeling. The study found that ipamorelin dose-dependently increased LGR from 42 µm/day in the vehicle group to 52 µm/day in the highest-dose group, along with a pronounced dose-dependent effect on body weight gain. The study noted that total IGF-I levels, IGFBPs, and serum markers of bone formation and resorption were not significantly altered, and characterized the pituitary GH response as marginally reduced after ipamorelin treatment — consistent with the expected receptor desensitization from repetitive dosing.
Human Pharmacokinetic Data
Ipamorelin is unusual among research peptides in having published human pharmacokinetic data from a dose-escalation trial. A 1999 study by Gobburu et al. published in Pharmaceutical Research enrolled healthy male volunteers at five intravenous infusion rates and characterized both the PK and GH response using a population pharmacokinetic-pharmacodynamic (PK/PD) model. The study found that ipamorelin displayed dose-proportional pharmacokinetics with a terminal half-life of approximately 2 hours, a clearance of 0.078 L/h/kg, and a single episodic GH release peak at approximately 0.67 hours post-infusion at all dose levels. The SC50 (concentration for half-maximal GH stimulation) was estimated at 214 nmol/L. This study represents the primary published human pharmacokinetic reference for ipamorelin; it was not a clinical efficacy or safety trial and did not assess therapeutic endpoints.
Gastrointestinal Motility in Rodent Models
A 2009 study by Venkova et al., published in the Journal of Pharmacology and Experimental Therapeutics, investigated whether ipamorelin could accelerate GI transit in a rodent model of postoperative ileus (POI). The study found that repetitive intravenous dosing of ipamorelin significantly increased cumulative fecal output, food intake, and body weight gain compared to vehicle in surgically manipulated rats, and concluded that ipamorelin's ghrelin-receptor agonism may have utility in GI motility research contexts. This study exemplifies the breadth of research interest in GHS-R1a agonism beyond GH-axis effects.
GHS-R1a Imaging and Receptor Characterization
More recently, ipamorelin has been used as a reference peptidomimetic in receptor-binding research. A 2018 study by Fowkes et al. in the European Journal of Medicinal Chemistry evaluated fluorinated derivatives of GHS peptides — including ipamorelin — as candidate PET imaging probes targeting GHS-R1a, which is overexpressed in certain carcinoma types. The study characterized ipamorelin's binding affinity profile at the ghrelin receptor as part of a comparative structure-activity investigation across peptidic and peptidomimetic GHS families.
Cachexia and Weight Loss Models
A 2024 study by Lu et al. in Physiology & Behavior compared the GHS-R1a agonists anamorelin and ipamorelin in a ferret model of cisplatin-induced emesis and weight loss. The study found that both ipamorelin and anamorelin administered intraperitoneally inhibited cisplatin-induced weight loss during the delayed phase by approximately 24%, though neither compound affected acute or delayed emesis via this route. This study adds to the research literature characterizing GHS-R1a agonists in metabolic and oncology-adjacent preclinical contexts.
What Is Ipamorelin's Evidence Tier? An Honest Assessment
Accurately representing the evidence base for ipamorelin requires distinguishing between its well-characterized receptor pharmacology and the much thinner body of human clinical data. The table below summarizes the landscape as documented in peer-reviewed literature:
| Evidence Level | Status for Ipamorelin (as of 2026) |
|---|---|
| Human randomized controlled efficacy trials | Not available; human data limited to one dose-escalation PK/PD study in healthy volunteers |
| Human pharmacokinetic data | Present — Gobburu et al. (1999) documented PK parameters and GH response across 5 dose levels in men |
| Preclinical animal studies | Multiple peer-reviewed rodent and swine studies documenting GH release, selectivity, bone growth, and GI effects |
| In vitro receptor binding data | Present — GHS-R1a binding affinity characterized in multiple studies |
| FDA approval status | Not approved for any human use |
| WADA status | Prohibited — Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) |
The critical distinction to state plainly: ipamorelin's selectivity profile — its documented lack of ACTH/cortisol elevation at GH-releasing doses — is a preclinical finding in swine, not a clinical observation in humans. Preclinical pharmacology does not guarantee the same selectivity profile across human physiology. No large, placebo-controlled human efficacy trial has been published demonstrating ipamorelin's effects on GH levels, body composition, or any other outcome in human subjects as of 2026.
What Is Ipamorelin's Regulatory Status?
FDA (United States)
Ipamorelin is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no approved indication, no authorized human dosing protocol, and is not available through lawful commercial channels as a therapeutic agent. The FDA classifies growth hormone secretagogues as compounds subject to regulatory scrutiny given their potential for off-label misuse. Researchers should consult current FDA guidance directly.
WADA (World Anti-Doping Agency)
Growth hormone secretagogues — including ipamorelin — are classified under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List. S2 covers all GH-releasing peptides and mimetics, prohibited both in-competition and out-of-competition. Athletes subject to WADA rules are prohibited from using ipamorelin in any context.
Frequently Asked Questions About Ipamorelin
Is ipamorelin FDA approved?
No. Ipamorelin is not approved by the FDA for any therapeutic use in humans. It is a research compound studied primarily in preclinical rodent and swine models, with limited human pharmacokinetic data from a single dose-escalation trial. It has no approved indication, no authorized human dosing protocol, and is not legally available as a drug or dietary supplement in the United States.
What makes ipamorelin selective compared to GHRP-6 and GHRP-2?
In the landmark Raun et al. (1998) study published in the European Journal of Endocrinology, ipamorelin did not significantly elevate ACTH or cortisol in swine even at doses more than 200-fold above the GH-releasing ED50 — in contrast to both GHRP-6 and GHRP-2, which produced significant ACTH and cortisol responses. This selectivity profile, observed in a preclinical swine model, led the authors to describe ipamorelin as the first GHRP-receptor agonist with GH-selectivity comparable to GHRH. This is a preclinical finding and has not been replicated in large human trials.
What is ipamorelin's evidence tier?
Ipamorelin is a Tier 2 compound in the Legendary Labz framework: multiple peer-reviewed preclinical studies with consistent findings on GH release and receptor pharmacology, plus limited human pharmacokinetic data. It does not meet the Tier 1 threshold because no large, placebo-controlled human efficacy RCTs have been published. Full evidence-tier methodology is documented in the guide.
Is ipamorelin on the WADA Prohibited List?
Yes. The WADA Prohibited List classifies growth hormone secretagogues, including ipamorelin, under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. The prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules.
Go deeper: This compound is one of 48 documented in the Legendary Labz Peptide Research Guide — a 224-page, evidence-tiered reference with primary citations throughout. Read a free compound profile.
Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources — read them in full. Must be 18+.